Key discoveries offer significant hope of reversing antibiotic resistance
30 October 2017
Two recent studies led by the University of Bristol provide significant new hope in the fight against antibiotic resistance. By identifying what makes some bacteria resistant to the most commonly prescribed antibiotics, and how this can be reversed, the findings have demonstrated potentially life-saving consequences and could help reverse the tide of antibiotic resistance.
Resistance to antibiotics is becoming increasingly prevalent and threatens to undermine healthcare systems across the globe. Antibiotics including penicillins, cephalosporins and carbapenems are known as β-lactams and are the most commonly prescribed worldwide.
In the first paper, University of Bristol researchers defined the relative importance of two mechanisms associated with β-lactam antibiotic resistance. In one, bacteria restrict the entry of antibiotics into the cell; in the other, bacteria produce an enzyme (a β-lactamase), which destroys any antibiotic that gets into the cell. The latter was found to be the more important of the two mechanisms. These findings imply that if chemicals could be developed to inhibit β-lactamase enzymes, a significant proportion of antibiotic resistance could successfully be reversed.
Building on these findings, and working in partnership with chemists at the University of Oxford and the University of Leeds, in the second paper, Bristol researchers studied the effectiveness of two types of β-lactamase enzyme inhibitor in a bacterium known to be highly resistant to common antibiotics.*
Using a variety of approaches, the authors studied avibactam, an inhibitor that has recently been introduced into clinical practice, and a “bicyclic boronate” inhibitor, which was first reported by the Oxford/Leeds/Bristol team in 2016.
They found both inhibitors failed to consistently protect the β-lactam antibiotic, ceftazidime, from attack by the β-lactamase enzyme. However, when paired with a different β-lactam antibiotic =, aztreonam, the inhibitors worked extremely well and killed some of the most resistant bacteria ever seen in the clinic.**
Dr Matthew Avison, Reader in Molecular Bacteriology from the University of Bristol’s School of Cellular & Molecular Medicine, and senior author for both studies said:
“Our bacteriology research has further demonstrated that β-lactamases are the real “Achilles heel” of antibiotic resistance in bacteria that kill thousands of people in the UK every year.
“Structural/mechanistic work on β-lactamase enzymes, including that led by my colleague Dr Jim Spencer, is helping to drive the discovery of wave after wave of β-lactamase inhibitors, including the potentially game-changing bicyclic boronate class, shown to be effective in our research, and recently successful in phase one clinical trials.
“Two β-lactamase inhibitors have recently been licenced for clinical use: avibactam and vaborbactam. Our work shows that avibactam might more successfully be deployed with aztreonam instead of ceftazidime as its antibiotic partner. We are delighted to see that this combination has entered clinical trials, and has recently saved the life of a patient in the USA who was suffering from a previously untreatable infection.”
“This is an exciting time for researchers studying β-lactamase inhibitors. At the risk of sounding like King Canute, it is the first time for a decade that there is some genuine positivity about our ability to turn back the rising tide of β-lactam antibiotic resistance.”
*The World Health Organisation recently placed cephalosporin and carbapenem resistant Gram-negative bacteria of the Enterobacteriaceae and Non-Fermenter groups at the top of its Priority List of Pathogens where Research and Development of novel treatment strategies is needed. The first paper investigated cephalosporin and carbapenem resistance in Klebsiella pneumoniae, one of the most clinically important members of the Enterobacteriaceae group.
**In the second paper, researchers studied the abilities of two β-lactamase inhibitors to reverse cephalosporin and carbapenem resistance in a member of the Non-Fermenter group, Stenotrophomonas maltophilia. This bacterium causes severe infections in immunocompromised patients and is usually resistant to all β-lactam antibiotics because it produces two β-lactamase enzymes.
The work reported was funded by grants from the Antimicrobial Resistance Cross-Council initiative supported by the seven UK research Councils. For more information: https://www.mrc.ac.uk/research/initiatives/antimicrobial-resistance/tackling-amr-a-cross-council-initiative/
The University of Bristol is a centre of excellence for antimicrobial resistance research having received more funding than any other UK university from phase 1 of the Antimicrobial Resistance Cross-Council Initiative, including research projects in 4/6 faculties. The university leads the MRF’s National PhD Training Programme for Antimicrobial Resistance Research, and is involved in several projects in Official Development Assistance countries, including leading one of the first round of AMR Cross-Council Initiative Phase 2 (Global Challenges Research Fund) awards. For more information see: http://www.bristol.ac.uk/bristolbridge/